miR-122 silencing a novel therapy for HCV infections?
Committee on Biotechnology PAS ; Institute of Bioorganic Chemistry PAS
Hepatitis C (HCV) infection is one of major epidemiological, medical and social concerns in the modern world. In Poland, around 700 000 people have HCV, worldwide the number is as high as 170-180 million. Current treatment consists of pegylated interferon-alpha and ribavirin, but is limited by the resistance of the viral strains, adverse effects, and high costs. Since HCV infection is a major cause of liver cirrhosis and hepatocellular carcinoma, it is necessary to develop novel antiviral compounds with improved virological response and reduced toxicity. In this article, we describe the results of recent trials to fight the HCV infection using an antagonising miR-122 oligo-LNA probe in primates.
Biotechnologia, vol.90, 3 (2010)-.
oai:rcin.org.pl:71217 ; IChB B-85
Biblioteka Instytutu Chemii Bioorganicznej PAN
Creative Commons Attribution BY-SA 4.0 license
Institute of Bioorganic Chemistry of the Polish Academy of Science
Institute of Bioorganic Chemistry of the Polish Academy of Science
Oct 2, 2020
May 16, 2019
265
https://rcin.org.pl./publication/93100
Edition name | Date |
---|---|
Wyciszanie miR-122 - nowa terapia wirusowego zapalenia wątroby typu C? | Oct 2, 2020 |
Borkowska, Bożenna
Tyczewska, Agata Bąkowska-Żywicka, Kamilla
Bąkowska-Żywicka, Kamilla Tyczewska, Agata
Tyczewska, Agata Figlerowicz, Marek Twardowski, Tomasz
Sławińska, Anna Siwek, Maria